Phaseline

Targets › GUCY2D

GUCY2D (Retinal guanylyl cyclase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Ophthalmology; next expected readout May 2027.

Catalyzes the synthesis of cyclic GMP (cGMP) in cone and rod photoreceptors, playing an essential role in phototransduction. Restores cytoplasmic cGMP levels, thereby returning photoreceptor cells to their dark-adapted state via a Ca(2+)-dependent negative feedback loop. (UniProt, Q02846)

Open in Phaseline: the race on GUCY2D, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Atsena TherapeuticsATSN-101
Gene therapy for GUCY2D mutations
GUCY2DPhase 1Leber Congenital AmaurosisMay 2027

Conditions

Leber Congenital Amaurosis (1)

Modalities

small molecule (1)

Companies

Atsena Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.